Track the 젬백스 stock price and the full insider trade history of the company, a listed equity based in South Korea. Shares are listed on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 젬백스 has logged 140 reports. Market capitalisation: €449.2bn. The latest transaction was filed on 19 June 2026 (Purchase). Among the most active insiders: 젬앤컴퍼니. All data is accessible without an account.
138
Insider Decl.
n/a
Thresholds
€3m
74 ops.
Buy Volume
€2m
18 ops.
Sell Volume
19Σ signal
Buys €3m€2m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,365 of 28,065 companies
33.7
score / 100
Value
32
Quality
36
FCF yld-0.2%
Earn yld-2.2%
EV/EBITDA·
ROE·
Gross mgn43%
Net mgn-14%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Gemvax is a company operating in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative treatments and therapeutic solutions.